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Abstract
Background: Saphenous vein graft disease remains a major limitation of coronary artery bypass
graft surgery. The process of saphenous vein intimal hyperplasia begins just days after surgical
revascularization, setting the stage for graft atherosclerotic disease and its sequalae. Clopidogrel
improves outcomes in patients with atherosclerotic disease, and is effective at reducing intimal
hyperplasia in animal models of thrombosis. Therefore, the goal of this study will be to evaluate the
efficacy of clopidogrel and aspirin therapy versus aspirin alone in the prevention of saphenous vein
graft intimal hyperplasia following coronary artery bypass surgery.
Methods: Patients undergoing multi-vessel coronary artery bypass grafting and in whom at least
two saphenous vein grafts will be used are eligible for the study. Patients will be randomized to
receive daily clopidogrel 75 mg or placebo, in addition to daily aspirin 162 mg, for a one year
duration starting on the day of surgery (as soon as postoperative bleeding has been excluded). At
the end of one year, all patients will undergo coronary angiography and intravascular ultrasound
assessment of one saphenous vein graft as selected by randomization. The trial will be powered to
test the hypothesis that clopidogrel and aspirin will reduce vein graft intimal hyperplasia by 20%
compared to aspirin alone at one year following bypass surgery.
Discussion: This trial is the first prospective human study that will address the question of
whether clopidogrel therapy improves outcomes and reduces saphenous vein graft intimal
hyperplasia following cardiac surgery. Should the combination of clopidogrel and aspirin reduce the
process of vein graft intimal hyperplasia, the results of this study will help redefine modern
antiplatelet management of coronary artery bypass patients.
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Background
Coronary artery bypass graft surgery (CABG) is the most
durable approach for the treatment of ischemic heart dis-
ease [1], with >400,000 procedures performed annually
in the United States alone [2]. Despite the increasing
application of arterial conduits during CABG, the saphen-
ous vein remains the most common conduit, employed
for more than 70% of grafts [3]. However, saphenous vein
graft (SVG) disease presents an important clinical prob-
lem. Even with aggressive medical therapy [4-11], up to
15% of vein grafts occlude in the first year after bypass sur-
gery. Between 1 and 6 years, the graft attrition rate is 1%
to 2% per year, and between 6 and 10 years it rises to 4%
per year. By 10 years after surgery, only 60% of grafts are
patent and only 50% of patent vein grafts are free of sig-
nificant stenosis. In addition, native coronary artery dis-
ease progresses in 5% of patients annually [12-15].
Reflecting the graft and native vessel attrition, this popu-
lation is at high risk for subsequent ischemic events,
including death, myocardial infarction (MI) and stroke
[14]. Further revascularization, either reoperation or per-
cutaneous coronary intervention, is required in 4% of
patients by 5 years, 19% of patients by 10 years and 31%
of patients by 12 years after the initial bypass surgery
[3,16].
The process of SVG disease is composed of three mecha-
nistically interlinked stages: thrombosis, intimal hyper-
plasia, and atherosclerosis [13,14,16-18]. Early graft
thrombosis can occur at the time of surgery secondary to
focal endothelial disruption [19,20]. Grafts that survive
this early period develop a progressive thickening of the
media that begins within days after implantation. This
process, termed intimal hyperplasia, is a consequence of
smooth muscle cell proliferation and extracellular matrix
protein synthesis [21,22]. Platelets play a fundamental
role in the process of smooth muscle cell proliferation and
intimal hyperplasia [23,24]. Intimal hyperplasia is
present in all grafts 1 month after implantation [25] and
forms a template for the development of superimposed
atherosclerotic changes [17,18]. With the passage of a suf-
ficient period of time, the thrombotic occlusion of vein
grafts is almost inevitable due to progressive atherosclero-
sis [17].
Despite its established benefit in patients with coronary
artery disease, aspirin therapy has numerous limitations.
It is a relatively weak antiplatelet agent and has no effect
on thrombin, which is believed to play a major role in
acute coronary syndrome [26]. Even with aspirin therapy
for secondary prevention, a large number of recurrent
events occur [27]. A significant proportion of patients
undergoing CABG may be aspirin resistant, defined as
undetectable platelet inhibition after one week of therapy
[28,29]. Depending on the population studied and the
specific definition of aspirin resistance, anywhere from
10–40% of patients appear to have an inadequate
antiplatelet response to aspirin [28,30]. Such patients
appear to be at increased risk for the development of vas-
cular events. In theory, these aspirin-resistant patients
may derive particular benefit from additional antiplatelet
therapy [31].
Clopidogrel is a thienopyridine antiplatelet agent that
inhibits ADP-dependent platelet activation and aggrega-
tion [32]. Sevenfold more potent than ticlopidine, clopi-
dogrel is free of its adverse side effects such as
neutropenia, diarrhea and rash [33]. Unlike aspirin
[24,34], clopidogrel has been shown to inhibit the process
of platelet-mediated intimal proliferation and smooth
muscle hyperplasia in laboratory experiments. In a cell
culture model, clopidogrel significantly inhibited platelet
adhesion to immobilized fibrinogen and also inhibited
platelet-dependent mitogenic signaling and DNA synthe-
sis in cultured coronary artery smooth muscle cells [35].
Similarly, in animal thrombosis models, clopidogrel but
not aspirin significantly inhibited platelet-mediated inti-
mal proliferation and smooth muscle hyperplasia
[33,36]. Furthermore, the combination of clopidogrel
with aspirin led to potent synergistic antithrombotic
effects and a decrease in myointimal proliferation com-
pared to either therapy alone [24,36,37].
Several large clinical trials have demonstrated that clopi-
dogrel reduces ischemic events and mortality in patients
with coronary and vascular disease [38-41]. In the CAPRIE
(Clopidogrel versus Aspirin in Patients with Ischemic
Events) trial, clopidogrel (75 mg/day) was demonstrated
to be significantly more effective than aspirin (325 mg/
day) in preventing vascular thrombotic events (ischemic
stroke, MI or vascular death) in patients with clinical evi-
dence of atherosclerotic disease (clopidogrel 9.78% vs.
aspirin 10.64%, relative risk reduction [RRR] 8.7%, p =
0.045) [38]. In patients presenting with acute coronary
syndromes, the CURE (Clopidogrel in Unstable angina to
prevent Recurrent ischemic Events) study demonstrated
that the combination of clopidogrel and aspirin was more
effective at reducing the primary outcome (cardiovascular
death, nonfatal MI or stroke) compared to aspirin alone
(clopidogrel and aspirin 9.3% vs. aspirin alone 11.4%,
RRR 20%, p < 0.001) [40]. Subgroup analysis from these
trials suggested that patients that underwent surgical
revascularization also benefited from clopidogrel
[39,42,43]. However, no trial to date has prospectively
evaluated the combined effects of clopidogrel plus aspirin
on saphenous vein graft disease after CABG.
There currently exists a clinical equipoise regarding the
optimal antiplatelet therapy for patients who have under-
gone coronary artery bypass surgery. While someCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:15 http://cvm.controlled-trials.com/content/6/1/15
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clinicians believe in the beneficial effects of clopidogrel,
the increased risk of bleeding and the lack of data in CABG
patients make it impossible to establish definitive recom-
mendations. We therefore propose the Clopidogrel after
Surgery for Coronary Artery Disease (CASCADE) study, a
randomized, placebo-controlled trial comparing clopi-
dogrel plus aspirin versus aspirin alone in CABG patients
revascularized with saphenous vein. The primary aim of
this study will be to evaluate the effect of combined
antiplatelet therapy on the reduction of SVG intimal
hyperplasia one year after CABG, through the assessment
of intimal area by intravascular ultrasound (IVUS). Sec-
ondary aims will evaluate the safety of clopidogrel admin-
istration following CABG with regards to bleeding
complications. We hypothesize that the combination of
clopidogrel with aspirin will reduce the SVG intimal
hyperplasia (intimal area) by 20% one year post-CABG
compared to the usual antiplatelet therapy of aspirin
alone.
Methods
Study Population and Recruitment Procedure
The study population will include all patients undergoing
multi-vessel elective or urgent CABG using at least two
saphenous vein grafts at the University of Ottawa Heart
Institute (OHI) over the study period (see Table 1 for
inclusion and exclusion criteria). Patients undergoing off-
pump CABG (OPCAB) will also be eligible for this study,
as long as at least two saphenous vein grafts are used.
OPCAB is performed in order to avoid the hazards associ-
ated with standard CABG, such as cardiopulmonary
bypass and aortic cross-clamping, and is carried out at the
discretion of the surgeon in patients deemed to be at
higher risk of thromboembolic or renal complications
during surgery. All CABG patients at the OHI will be
triaged pre-operatively, and study eligible patients will be
selected and approached by the study nurse to explain the
trial and obtain consent.
Description of Intervention and Control
A prospective randomized double-blinded placebo-con-
trolled study will be conducted from November 2005 to
November 2007 in order to achieve the study objectives.
Patients will be recruited over the first 12 months of the
study, and graft evaluation for each patient will occur over
the following 12 months (one year after surgery for each
patient). Patients will be randomized into an experimen-
tal group (receiving clopidogrel) or a control group (pla-
cebo). The placebo and clopidogrel medications will be
prepared by the Bristol Myers-squibb Sanofi Canada Part-
nership and appear identical. Medication administration
and data collection will be performed in a double-blind
manner, such that neither the patient nor the healthcare
personnel will be aware of the medication assignment.
Recruitment and written consent will be performed prior
to surgery. However, patients will not be randomized
until after surgery has been completed and clinical stabil-
ity ensured. Patients that are bleeding excessively after sur-
gery (chest tube output > 200 cc/hr) or those requiring
high levels of hemodynamic support (more than 2 ino-
tropes and/or intra-aortic balloon pump) will not be ran-
domized into the study.
After surgery, the study medication will be administered
via nasogastric tube when the chest tube drainage has
decreased to ≤50 cc/hr for 2 hours. Each patient will
receive either clopidogrel 75 mg or placebo, in addition to
enteric coated aspirin 162 mg (Figure 1). The study drug
and aspirin 162 mg will be repeated orally in the same
dose once daily for the duration of one year. Because post-
CABG patients are relatively aspirin resistant following
surgery, the aspirin dose of 162 mg will ensure adequate
platelet inhibition in those patients randomized to aspi-
rin alone. Furthermore, 162 mg falls within the safety
window of combining aspirin with clopidogrel
[30,40,44].
Allocation Procedure
A stratified random design allocation will be utilized to
account for the presence or absence of diabetes, as well as
the use or nonuse of cardiopulmonary bypass (standard
CABG versus OPCAB). A block randomization technique
will ensure an equal distribution of diabetic patients in
both arms of the trial and an equal distribution of OPCAB
patients. The randomization schedule will be generated
using SAS 9.1 software (SAS, Cary, NC). All patients and
study personnel will be blinded to the treatment assign-
ment, which will be performed by the hospital pharmacy.
Concomitant Medication and Treatments
Patients will receive concomitant therapies in both groups
as recommended by the current American College of Car-
diology / American Heart Association guidelines. This will
include smoking cessation counseling and the administra-
tion of aspirin, beta blockers, angiotensin converting
enzyme inhibitors, and lipid lowering medications. Target
LDL values will be those recommended as per current
guidelines [45-47] and will be assessed during the study
follow-up period. Routine peptic ulcer prophylaxis will
not be administered in order to fully evaluate gastrointes-
tinal side effects.
Diabetic patients will be eligible for enrollment in this
study, regardless of their preoperative need for insulin
therapy, and will be allocated equally into both groups
through stratified randomization. Diabetic patients will
have aggressive perioperative glycemic control, including
an intravenous insulin infusion both in the operating
room and in the intensive care unit, and a subcutaneous
insulin sliding scale while recovering on the surgical ward.Current Controlled Trials in Cardiovascular Medicine 2005, 6:15 http://cvm.controlled-trials.com/content/6/1/15
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Figure 1
text
Patients recruited before surgery
Preoperative CBC and lipid profile
Randomization when chest tube drainage
<5 0c c / h rx2h r s
Patients withdrawn from study if postoperative
bleeding complications, warfarin requirements, etc.
CBC and lipid profile at one month F/U
IVUS and angiogram at one year
CBC and lipid profile at one year F/U
Clopidogrel 75 mg or placebo, plus daily aspirin 162 mg
CABG or OPCAB Surgery
Postoperative chest tube drainage and
bleeding complications recorded
Discharge home
Physician follow-up at 1 and
6 months
Nurse phone calls at 3, 6, 9
and 12 months
Assessment of major adverse coronary events (MI,
CVA, angina, etc.) and bleeding complicationsCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:15 http://cvm.controlled-trials.com/content/6/1/15
Page 5 of 9
(page number not for citation purposes)
Once drinking well, diabetic patients will be restarted on
their original preoperative diabetic regimens (oral agents
and/or insulin therapy). The treatment of diabetes during
this study will be closely monitored in collaboration with
an endocrinologist specializing in the management of
diabetes.
Primary Outcomes
The primary endpoint of this study will be to assess
whether the addition of clopidogrel to aspirin reduces
intimal hyperplasia in saphenous vein grafts 12 months
after bypass surgery, as assessed by IVUS. Patients will
undergo IVUS imaging 12 months post-CABG, and the
average intimal area in the proximal 40 mm of one vein
graft per patient will be assessed.
Secondary Outcomes
At the time of intravascular ultrasound, coronary and graft
angiography will also be performed to assess vein graft
patency and areas of stenosis. Although this trial will not
be sufficiently powered for such a purpose, this data will
be obtained whilst gathering information pertaining to
the primary outcome.
Endpoints related to safety will also be documented, both
at the time of surgery as well as during the one year of
study drug administration. After surgery, data will be
recorded regarding chest tube blood loss, blood product
transfusions, bleeding requiring tube thoracostomy or
sternal re-opening, perioperative MI, and gastrointestinal
complications. Complete blood counts (CBC) will assess
the hemoglobin level in the immediate postoperative
period and during the one year follow-up. In addition, the
incidence of major adverse cardiovascular events follow-
ing CABG (mortality, MI, cerebrovascular accident, hospi-
talization for coronary ischemia, need for coronary
intervention) will be recorded.
IVUS Procedure
Intravascular ultrasound will be used to assess the area of
intimal hyperplasia present in saphenous vein grafts at 12
months after surgery. IVUS differs from angiography by
providing cross-sectional images of both the vessel wall
and lumen with high resolution. The process of intimal
hyperplasia is easily detectable and quantifiable by IVUS,
but may completely escape visualization by angiography.
At one year following CABG, vein graft intimal hyperpla-
sia is universally present.
Efforts will be made to schedule all patients at 52 ± 2
weeks from the day of randomization (Figure 1). The
IVUS procedure will first start with angiography of the
native coronary arteries and the coronary bypass grafts.
This will allow assessment of the progression of native
coronary artery atherosclerosis (both in grafted and non-
grafted vessels). Patency of all bypass grafts will be scored
using 1) the Fitzgibbon method [14] and 2) the TIMI clas-
sification [48]. Patency of the coronary arteries will be
assessed by the TIMI method.
IVUS studies will be performed using a 40 MHz imaging
catheter (Atlantis® SR Pro, Boston Scientific). This catheter
is a monorail system and has 6F guiding catheter compat-
ibility. All IVUS imaging will be done with the administra-
tion of unfractionated heparin (70 units per kg, minimum
4000 units) before the introduction of the guidewire into
a vein graft. Each patient will have at least two vein grafts
implanted at the time of surgery. However, imaging of
more than one graft is not clinically advisable for safety
and practical reasons. In order to minimize bias, the car-
diologist performing the IVUS procedure will be blinded
to the treatment allocation, and the selection of the SVG
for IVUS imaging will be randomized. For this purpose, a
sequence randomization scheme (based on the number
of vein grafts) will produce a random sequence of num-
bers for each patient, such as "2, 1 and 3". These numbers
will correspond to the position of the proximal anastomo-
sis of each SVG on the ascending aorta (by increasing
number from cranial to caudal, starting from 1). The graft
whose random number is produced first will be selected
for intubation with the IVUS catheter, unless 1) this par-
ticular graft showed more than 50% stenosis on the selec-
tive angiography performed immediately prior, or 2)
access to this graft is technically difficult (graft tortuosity,
difficult graft intubation). If any of the above two
instances is encountered, the graft with the next number
in the randomization sequence will instead be selected for
IVUS, and so on. Graft exclusion for whatever basis (either
because >50% stenosis or technically difficult access) will
be recorded for all patients in each group.
Once the randomized graft selection has been completed,
the actual IVUS procedure will take place. Intracoronary
nitroglycerin (200 µg) will be given before advancing the
IVUS catheter, and a 6F guiding catheter will be used to
engage the vein graft. Then, a 0.014" coronary angioplasty
guidewire will be advanced distally through the vein graft
and positioned into the native coronary artery. The IVUS
catheter will then be advanced into the graft at least 50
mm beyond the aorto-ostial anastomosis. The guiding
catheter will then be disengaged to ensure visualization of
the aorto-ostial anastomosis on pullback. This is essential
because the aorto-ostial anastomosis will be the only
landmark available to assure measurements of the proxi-
mal portion of each graft are comparable between groups.
IVUS imaging will be done using a validated motorized
pullback device at 0.5 mm/sec. Each study will be
recorded on a separate S-VHS videotape. Only one quality
pullback will be needed per graft, but a second pullbackCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:15 http://cvm.controlled-trials.com/content/6/1/15
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may be repeated if the first set of pullback images were
judged suboptimal in quality.
IVUS Analysis
The IVUS images will be sent to an independent core lab-
oratory and interpreted by an experienced cardiologist
blinded to treatment allocation. The methods for the
analysis have been previously reported and validated [49].
Briefly, using the aorto-ostial anastomosis as a landmark,
the most proximal 40 mm of vein graft will be analyzed.
The video images will be digitized and measurements of
lumen, intimal hyperplasia, and external elastic lamina
areas will be available for each digitized cross section. Inti-
mal hyperplasia volumes will be computed by multiply-
ing the corresponding areas of each of the cross-sections
by the distance between slices and by adding the products.
For the purpose of this study, the mean plaque area per
patient for the 40 mm-analyzed segment will be used for
comparison between treatment groups.
Sample Size
The trial will be powered to test the hypothesis that clopi-
dogrel and aspirin should reduce vein graft intimal hyper-
plasia by 20% compared to aspirin alone at one year
following bypass surgery. According to Hozumi et al., at
one year, the mean intimal area of angiographically nor-
mal saphenous vein grafts is 5.26 mm2, with a standard
deviation of 1.38 mm2  [50]. Intravascular ultrasound
imaging will be performed at follow-up in one vein graft
per patient. In order to account for potential angiographic
refusals and study withdrawals, approximately 100
patients in total will be required to test the null hypothesis
with an α value of 0.05 and a power of 0.90.
Data Collection and Safety Monitoring
Intimal area will be recorded at the time of IVUS one year
after CABG. Vein graft patency and stenosis will be
assessed by angiography. The incidence of major adverse
coronary events and bleeding complications will be docu-
mented during postoperative clinic visits at one month,
six months and twelve months after surgery. Telephone
home assessments every three months will also be used to
document events. All serious adverse events will be
reported to the ethics committee. The development of
serious adverse events that might be attributable to clopi-
dogrel will lead to the termination of the study drug.
Ethics
The study will adhere to the highest research ethics stand-
ards of the OHI. This protocol follows the CONSORT
guidelines [51] and was approved on July 19, 2005 by the
University of Ottawa Heart Institute Human Research Eth-
ics Board.
Statistical Analysis
Vein graft intimal area, the primary outcome of the study,
will be compared between the two randomization groups
using two-sided Student's t tests. Vein graft patency will be
compared using a Fisher's exact test. With respect to the
secondary outcomes, continuous data will be compared
between the two groups using two-sided Student's t tests,
two-sample Wilcoxon rank-sum tests, or ANOVA as
appropriate, and a Fisher's exact test will be used for cate-
gorical data. In order to assess possible interactions
between patient characteristics (such as diabetes) and
treatment outcomes, an exploratory analysis using multi-
variate linear regression will be performed. In the improb-
able event that all vein grafts are occluded and IVUS
cannot be performed in a particular patient undergoing
the one-year study, a value of five times the mean intimal
area (decided a priori) will be assigned for that patient.
Discussion
The CASCADE study is a novel randomized double-blind
placebo-controlled trial that will help clarify the contro-
versial issue of antiplatelet therapy following CABG sur-
gery. Specifically, it will answer the questions of whether
the addition of clopidogrel to aspirin is safe following car-
diac surgery and whether it reduces saphenous vein graft
intimal hyperplasia. Although subgroup analyses of previ-
ous trials have suggested a benefit of clopidogrel in car-
diac surgery patients [39,42,43], no trial to date has
specifically focused on the clinical or angiographic out-
comes in patients treated with clopidogrel therapy imme-
diately after surgical revascularization. Should the
combination of clopidogrel and aspirin reduce the proc-
ess of vein graft intimal hyperplasia, the CASCADE trial
has the potential to redefine modern antiplatelet manage-
ment of coronary artery bypass patients.
We believe that the strengths of this study are its rand-
omized and blinded design. Patients will be randomized
into two treatment groups, and graft selection for IVUS
imaging will be randomized within each patient. Blinding
will occur for all patients and health care providers, and
the IVUS and angiogram images will be interpreted by an
external blinded core laboratory. While the process of inti-
mal hyperplasia may be reduced in the trial, the study will
not be powered to demonstrate a difference in
angiographic patency or freedom from coronary events
following CABG. In order to demonstrate a difference in
either of these outcomes, a considerably larger sample size
and longer follow-up period would be required.
The results of this randomized trial will be generalizable
to all patients undergoing standard CABG or OPCAB sur-
gery with saphenous vein. Although the trial enrolment is
limited to lower risk patients, it is anticipated that the
results will also be applicable to higher risk patients withCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:15 http://cvm.controlled-trials.com/content/6/1/15
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severe ischemic left ventricular dysfunction or those
undergoing redo-CABG. High-risk patients participating
in previous clopidogrel studies have been found to derive
an enhanced benefit with the combined treatment of
clopidogrel and aspirin [42]. Furthermore, there is no rea-
son to anticipate differences in the pathophysiology of
vein graft disease between high risk patients and those of
the proposed study group.
Conclusion
Saphenous vein graft disease continues to be a major lim-
itation of surgical revascularization for coronary artery
disease. The process of saphenous vein intimal hyperpla-
sia begins just days after surgery, setting the stage for graft
atherosclerotic disease and its sequalae. Clopidogrel has
been demonstrated to improve outcomes in patients with
coronary and vascular disease, and it is effective at reduc-
ing intimal hyperplasia in animal models of thrombosis.
However, no prospective study to date has been con-
ducted in humans regarding the use of clopidogrel after
CABG to prevent vein graft intimal hyperplasia. The CAS-
CADE trial is a randomized, placebo-controlled trial com-
paring clopidogrel plus aspirin versus aspirin alone in
CABG patients revascularized with saphenous vein. The
effects of clopidogrel on vein graft intimal hyperplasia
will be studied with coronary angiography and intravascu-
lar ultrasound one year following CABG.
Abbreviations
CABG – coronary artery bypass graft surgery
CASCADE – Clopidogrel after Surgery for Coronary Artery
Disease Trial
CBC – complete blood counts
IVUS – intravascular ultrasound
MI – myocardial infarction
OHI – University of Ottawa Heart Institute
OPCAB – off-pump coronary artery bypass graft surgery
Table 1: Study Inclusion and Exclusion Criteria
Inclusion Criteria: Reason:
- Patients undergoing primary multi-vessel CABG with at least two 
saphenous vein grafts, with or without cardiopulmonary bypass
- The population of clinical interest
Preoperative Exclusion Criteria: Reason:
- Emergency surgery - Unable to obtain consent
- Valve surgery - Requirement of postoperative anticoagulation
- Redo CABG - Higher risk of postoperative bleeding and low cardiac output 
syndrome
- Left ventricle ejection fraction <25% - Higher risk of postoperative low cardiac output syndrome and 
mortality
- Serum creatinine >130 µmol/L - Contraindication to use of postoperative angiography
- Preoperative use of clopidogrel (with the exception of the current 
admission)
- Contraindication to randomization, confounding of results
- Preoperative use of warfarin - Requirement of postoperative anticoagulation
- Allergy to aspirin or clopidogrel - Contraindication to use of aspirin or clopidogrel
- History of cerebrovascular accident - Concurrent indication for clopidogrel
- History of severe liver disease - Contraindication to use of clopidogrel
- Morbid obesity - Unable to perform postoperative angiography
- Residence outside of Ottawa region - Unable to perform postoperative angiography
- Current malignancy - Higher risk of early postoperative mortality
- Inability to provide informed consent - Ineligible for research study enrollment
Postoperative Exclusion Criteria: Reason:
- Low cardiac output syndrome with inotropic support for greater than 
24 hours
- Unstable patient unlikely to benefit from treatment
- Recurrent ventricular arrhythmias - Unstable patient unlikely to benefit from treatment
- Intubation for more than 24 hours - Unstable patient unlikely to benefit from treatment
- Postoperative bleeding or cardiac tamponade requiring surgical 
exploration
- Contraindication to use of clopidogrel
- Postoperative gastrointestinal bleeding - Contraindication to use of clopidogrel
- Postoperative warfarin requirement - Contraindication to use of clopidogrelCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:15 http://cvm.controlled-trials.com/content/6/1/15
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RRR – relative risk reduction
SVG – saphenous vein graft
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